Skip to main content
SBFM
NASDAQ Life Sciences

Sunshine Biopharma Resolves Dispute with Former Nora Pharma President for ~$1.06M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.13
Mkt Cap
$4.438M
52W Low
$2
52W High
$24.3
52W Position info
6.5% above low
Off High info
91% below high
Rel. Volume
Market data snapshot near publication time

SBFM is trading near its 52-week low of $2 (6.5% above the low).

Summary

Sunshine Biopharma settled a dispute with former Nora Pharma president Malek Chamoun for CAD$1.5 million (~US$1.06 million), requiring him to sell all his shares and releasing him from non-compete obligations.


Key Events · Legal and Risk Events · SBFM

  • Settlement Agreement Signed

    On July 8, 2026, Sunshine Biopharma and its subsidiary Nora Pharma entered into a settlement with former Nora president Malek Chamoun, agreeing to pay CAD$1,500,000 (~US$1,058,565) to resolve all disputes.

  • Financial Impact

    The settlement payment of ~$1.06 million represents a significant cash outlay for a company with a market cap of only $4.4 million and recent financial distress, though it eliminates litigation risk.

  • Share Sale Requirement

    Chamoun must sell all his Sunshine Biopharma common shares within 30 days of the agreement, which could create near-term selling pressure on the stock.

  • Non-Compete Release

    The agreement releases Chamoun from all non-competition and non-solicitation obligations, potentially allowing him to compete with Nora Pharma.


Analysis · SBFM · Life Sciences

A legal dispute with Malek Chamoun, the former president of the Nora Pharma subsidiary, has been settled for CAD$1.5 million (~US$1.06 million). While the mutual release of all claims removes a significant legal overhang, the agreement requires Chamoun to sell all his Sunshine shares within 30 days, potentially adding selling pressure. The company also released Chamoun from non-compete obligations, which could introduce competitive risk. For a micro-cap with a market cap of only ~$4.4 million and recent financial distress, a $1.06 million cash payment is a material use of scarce resources, though it eliminates the uncertainty and cost of litigation.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SBFM was trading at $2.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $2.00 to $24.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SBFM - Latest Insights

SBFM
Nov 18, 2026, 4:05 PM EST
Filing Type: S-1
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $2.23 info
Change: -$0.1751 (-7%) info
Market Cap: $1.837M info
SBFM
Nov 12, 2026, 11:56 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $2.23 info
Change: -$0.4651 (-17%) info
Market Cap: $1.837M info
SBFM
Nov 12, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.23 info
Change: -$0.5751 (-20%) info
Market Cap: $1.837M info
SBFM
Nov 12, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $2.23 info
Change: -$0.5651 (-20%) info
Market Cap: $1.837M info
SBFM
Oct 22, 2026, 9:25 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.1638
Real-time Price: $2.23 info
Change: Reverse Stock Split info
Market Cap: $1.837M info